Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 1/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.53 |
| ▸ | NAMPT | P43490 | 3/20 | 0.53 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.49 |
| ▸ | LIPE | Q05469 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 3/20 | 0.47 |
| ▸ | DRD4 | P21917 | 3/20 | 0.47 |
| ▸ | DRD3 | P35462 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15045192 | 0.88 | SRD5A1 (0.57) | SRD5A1EPHX2NAMPTSCD5HRH3 | |
| Hydrochloric Acid SCHEMBL2775020 | 0.85 | SRD5A1 (0.54) | SRD5A1EPHX2NAMPTSCD5CYP2C9 | |
| SCHEMBL18318837 | 0.83 | SRD5A1 (0.50) | SRD5A1EPHX2NAMPTSCD5LIPE | |
| SCHEMBL18318131 | 0.83 | MAP4K4 (0.53) | SRD5A1EPHX2NAMPTSCD5HRH3 | |
| SCHEMBL2091338 | 0.83 | EPHX2 (0.57) | SRD5A1EPHX2NAMPTSCD5 | |
| SCHEMBL5271411 | 0.82 | EPHX2 (0.59) | SRD5A1EPHX2NAMPTSCD5CYP2C9 | |
| SCHEMBL18318797 | 0.81 | SRD5A1 (0.48) | SRD5A1EPHX2NAMPTSCD5LIPE | |
| SCHEMBL4578845 | 0.81 | EPHX2 (0.58) | SRD5A1EPHX2NAMPTSCD5CYP2C9 | |
| SCHEMBL31256910 | 0.80 | NAMPT (0.50) | SRD5A1EPHX2NAMPTSCD5CYP2C9 | |
| SCHEMBL14412821 | 0.80 | EPHX2 (0.57) | SRD5A1EPHX2NAMPTSCD5CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230145481-A1 | SUBSTITUTED BENZENECARBOXAMIDES AS IL-17A MODULATORS | DICE ALPHA, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230141212-A1 | SUBSTITUTED BENZENECARBOXAMIDES AS IL-17A MODULATORS | DICE ALPHA, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230141212-A1 | SUBSTITUTED BENZENECARBOXAMIDES AS IL-17A MODULATORS | DICE ALPHA, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230145481-A1 | SUBSTITUTED BENZENECARBOXAMIDES AS IL-17A MODULATORS | DICE ALPHA, INC. | 2023-05-11 | — | — | US | disclosed |
| US-11274094-B2 | Substituted benzenecarboxamides as IL-17A modulators | DICE ALPHA, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| US-20210101886-A1 | IL-17A MODULATORS AND USES THEREOF | DICE ALPHA, INC. | 2021-04-08 | — | — | US | disclosed |
| WO-2021055376-A1 | IL-17A MODULATORS AND USES THEREOF | DICE ALPHA, INC. (US) | 2021-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230145481-A1 | SUBSTITUTED BENZENECARBOXAMIDES AS IL-17A MODULATORS | IL17A, IL2, IL23R | SRD5A1 1867/4885EPHX2 1557/4885NAMPT 2253/4885 |
| US-11274094-B2 | Substituted benzenecarboxamides as IL-17A modulators | IL17A, IL23R, IL18 | SRD5A1 3165/4885EPHX2 1611/4885NAMPT 1968/4885 |
| US-20230141212-A1 | SUBSTITUTED BENZENECARBOXAMIDES AS IL-17A MODULATORS | IL17A, IL2, IL23R | SRD5A1 1867/4885EPHX2 1557/4885NAMPT 2253/4885 |
| US-20210101886-A1 | IL-17A MODULATORS AND USES THEREOF | IL17A, IL2, IL36G | SRD5A1 2396/4885EPHX2 2137/4885NAMPT 1020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.